In yesterday’s Wall Street session, Clover Health Investments Corp (NASDAQ:CLOV) shares traded at $3.31, up 3.76% from the previous session.
CLOV stock price is now -6.54% away from the 50-day moving average and 53.31% away from the 200-day moving average. The market capitalization of the company currently stands at $1.66B.
With the price target of $6, Craig Hallum recently initiated with Buy rating for Clover Health Investments Corp (NASDAQ: CLOV). On October 07, 2024, UBS recently initiated its ‘Neutral’ rating on the stock quoting a target price of $4, while ‘Cowen’ rates the stock as ‘Market Perform’
In other news, Garipalli Vivek, Director bought 531,700 shares of the company’s stock on Aug 09 ’24. The stock was bought for $999,596 at an average price of $1.88. Upon completion of the transaction, the Director now directly owns 1,409,267 shares in the company, valued at $4.66 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Jun 17 ’24, Director Garipalli Vivek bought 877,567 shares of the business’s stock. A total of $1,000,426 was incurred on buying the stock at an average price of $1.14. This leaves the insider owning 877,567 shares of the company worth $2.9 million. A total of 24.68% of the company’s stock is owned by insiders.
During the past 12 months, Clover Health Investments Corp has had a low of $0.61 and a high of $4.71. The fifty day moving average price for CLOV is $3.558 and a two-hundred day moving average price translates $2.14633 for the stock.
The latest earnings results from Clover Health Investments Corp (NASDAQ: CLOV) was released for 2024-09-30. The net profit margin was -5.94% and return on equity was -28.69% for CLOV. The company reported revenue of $330.99 million for the quarter, compared to $306.03 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 8.16 percent.
